Yale University School of Medicine, United States
Disclosure information not submitted.
3A-01 - Cardiovascular Effectiveness of Semaglutide: Using Real-World Data to Predict Findings of the Ongoing SOUL Cardiovascular Outcomes Trial
Monday, August 25, 20258:15 AM - 8:30 AM ET
6C-03 - Using Real-World Data to Predict Findings of an Ongoing Phase IV Trial: Glycemic Control of Semaglutide vs Standard of Care
Tuesday, August 26, 20252:00 PM - 2:15 PM ET
